

ANTICIPATED ACQUISITION BY ILLUMINA, INC. OF PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Cancellation of merger reference

On 6 January 2020, the Competition and Markets Authority (CMA) cancelled the reference concerning the anticipated acquisition by Illumina, Inc. (Illumina) of Pacific Biosciences of California, Inc. (PacBio).

On 27 June 2019, the CMA, in exercise of its duty under section 33(1) of the Enterprise Act 2002 (the Act), referred the anticipated acquisition by Illumina of PacBio (the Proposed Merger) for further investigation and report by a group of CMA panel members (the Inquiry Group).

The terms of reference required the CMA to examine:

- (a) whether arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation; and
- (b) if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any markets in the UK for goods or services.

The CMA has received written assurances from Illumina and PacBio that the proposed acquisition by Illumina of PacBio has been abandoned.

The Inquiry Group, having had regard to those assurances and the evidence provided by Illumina and PacBio, is satisfied that Illumina and PacBio have, within the terms of section 37(1) of the Act, abandoned the proposal to make arrangements

of the kind mentioned in the reference. The Inquiry Group has consequently cancelled the reference in accordance with its duty under section 37(1) of the Act.

This cancellation will be published in accordance with requirements laid down by section 107(2)(a) and 107(4) of the Act.

Signed

Stuart McIntosh

Inquiry Group Chair